Two centuries ago in 1817, James Parkinson provided the first medical description of
Parkinson's disease, later refined by Jean-Martin Charcot in the mid-to-late 19th century to …

Parkinson's disease (PD) and atypical Parkinsonian syndromes are progressive
heterogeneous neurodegenerative diseases that share clinical characteristic of …

Over the past three decades, neuroimaging studies—including structural, functional and
molecular modalities—have provided invaluable insights into the mechanisms underlying …

Accurate differential diagnosis of parkinsonism is of paramount therapeutic and prognostic
importance. In addition, with the development of invasive therapies and novel disease …

The differential diagnosis of neurodegenerative brain diseases on clinical grounds is
difficult, especially at an early disease stage. Several studies have found specific regional …

Purpose There are no comprehensive guidelines for the use of FDG PET in the following
three clinical scenarios:(1) diagnostic work-up of patients with idiopathic Parkinson's …

Objective: Imaging of regional cerebral glucose metabolism with PET and striatal dopamine
D2/D3 receptors (D2R) with SPECT improves the differential diagnosis of parkinsonism. We …

Background Synaptic loss is a prominent and early feature of many neurodegenerative
diseases. Objectives We tested the hypothesis that synaptic density is reduced in the …

Frontal–subcortical circuits (FSCs) incorporate complex input from the central nervous
system to modulate the expression of cognition and emotion through behavior and …

There is increasing use of neuroimaging modalities, including PET, for diagnosing
dementia. For example, FDG-PET demonstrates hypometabolic regions in the posterior …